Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study
Open Access
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (14) , 2026-2034
- https://doi.org/10.1016/s0959-8049(03)00456-8
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Fatigue in cancer patients compared with fatigue in the general United States populationCancer, 2002
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001
- Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly DosingJournal of Clinical Oncology, 2001
- Efficacy of epoetin alfa in the treatment of anaemia of multiple myelomaBritish Journal of Haematology, 2001
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997